{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:49:29Z","timestamp":1790020169093,"version":"4.0.1"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","award":["KJS2419"],"award-info":[{"award-number":["KJS2419"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700130"],"award-info":[{"award-number":["81700130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cytogfr.2025.04.002","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:51:25Z","timestamp":1745326285000},"page":"66-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Mechanisms underlying resistance to CAR-T cell therapy and strategies for enhancement"],"prefix":"10.1016","volume":"83","author":[{"given":"Anran","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyue","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruonan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bofeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyuan","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8547-711X","authenticated-orcid":false,"given":"Xiaofeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.04.002_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.04.002_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.04.002_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/156652310791111001","article-title":"Building better chimeric antigen receptors for adoptive T cell therapy","volume":"10","author":"S. Bridgeman","year":"2010","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-3-030-41008-7_10","article-title":"CAR T-Cells","volume":"1244","author":"Nair","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.04.002_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BS9.0000000000000173","article-title":"CAR-T cell therapy: where are we now, and where are we heading?","volume":"5","author":"Wang","year":"2023","journal-title":"Blood Sci."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.04.002_bib9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.04.002_bib10","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2002-04-1041","article-title":"Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors","volume":"100","author":"Haynes","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.04.002_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.04.002_bib12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"issue":"18","key":"10.1016\/j.cytogfr.2025.04.002_bib14","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.04.002_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"issue":"13","key":"10.1016\/j.cytogfr.2025.04.002_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133476","article-title":"Fine-tuning through generations: advances in structure and production of CAR-T therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.cytogfr.2025.04.002_bib17","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.bulcan.2021.06.005","article-title":"How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?","volume":"108","author":"Huguet","year":"2021","journal-title":"Bull. du Cancer"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.04.002_bib18","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.04.002_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.hemonc.2021.09.004","article-title":"Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: what is the evidence?","volume":"15","author":"Kharfan-Dabaja","year":"2022","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib20","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","author":"Neelapu","year":"2023","journal-title":"Blood 141(19"},{"issue":"17","key":"10.1016\/j.cytogfr.2025.04.002_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174279","article-title":"Clinical and product features associated with outcome of DLBCL patients to CD19-targeted cAR T-cell therapy","volume":"13","author":"Lamure","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cytogfr.2025.04.002_bib22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/blood-2023-180242","article-title":"Multicenter, real-world study in patients with R\/R large B-cell lymphoma (LBCL) who received lisocabtagene maraleucel (liso-cel) in the United States (US)","volume":"142","author":"Crombie","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2025.04.002_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2025.04.002_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/sci-2020-029","article-title":"Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma","volume":"8","author":"Ding","year":"2021","journal-title":"Stem Cell Investig."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.04.002_bib26","article-title":"A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma","volume":"4","author":"Di Meo","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib27","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.04.002_bib28","first-page":"1456","article-title":"CAR-T therapy for multiple myeloma","volume":"64","author":"Ri","year":"2023","journal-title":"Rinsho Ketsueki"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.23736\/S0031-0808.20.04146-4","article-title":"CAR T cells targeting options in the fight against multiple myeloma","volume":"63","author":"Nicolini","year":"2021","journal-title":"Panminerva Med."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.04.002_bib30","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.04.002_bib31","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.1016\/j.bbmt.2018.12.623","article-title":"CS1 targeted chimeric antigen receptors (CAR) for treatment of multiple myeloma","volume":"25","author":"O'Neal","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/sci-2020-029","article-title":"Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma","volume":"8","author":"Ding","year":"2021","journal-title":"Stem Cell Invest."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.04.002_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/ejh.14145","article-title":"Update on the current and future use of CAR-T to treat multiple myeloma","volume":"112","author":"Gahvari","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.04.002_bib34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/CCO.0000000000000667","article-title":"Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"32","author":"Beauvais","year":"2020","journal-title":"Curr. Opin. Oncol."},{"issue":"13_ement","key":"10.1016\/j.cytogfr.2025.04.002_bib35","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1158\/1538-7445.AM2018-3572","article-title":"CAR T-cells targeting the kappa myeloma antigen for the treatment of multiple myeloma","volume":"78","author":"Gowrishankar","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.04.002_bib37","first-page":"1058","article-title":"Clinical development of CAR-T therapy for refractory multiple myeloma","volume":"59","author":"Ohmine","year":"2018","journal-title":"Rinsho Ketsueki"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.04.002_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9101422","article-title":"Novel CS1 CAR-T cells and bispecific CS1-BCMA CAR-T Cells effectively target multiple myeloma","volume":"9","author":"Golubovskaya","year":"2021","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.04.002_bib39","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.04.002_bib40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/17474086.2022.2081147","article-title":"Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma","volume":"15","author":"Davis","year":"2022","journal-title":"Expert Rev. Hematol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.04.002_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.04.002_bib42","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?","volume":"34","author":"D'Agostino","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.cytogfr.2025.04.002_bib44","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib45","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol. 16(6"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.04.002_bib46","first-page":"805","article-title":"[Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy]","volume":"44","author":"Zhou","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib47","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1186\/s12885-024-12651-6","article-title":"CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient's age, and tumor types","volume":"24","author":"Montagna","year":"2024","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.04.002_bib48","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.cytogfr.2025.04.002_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00383-18","article-title":"CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum","volume":"38","author":"Bagashev","year":"2018","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12885-019-5415-9","article-title":"Challenges of driving CD30-directed CAR-T cells to the clinic","volume":"19","author":"Grover","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.04.002_bib52","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cam4.3624","article-title":"Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma","volume":"10","author":"Yan","year":"2021","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.04.002_bib53","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.04.002_bib54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/ni0903-815","article-title":"What is trogocytosis and what is its purpose?","volume":"4","author":"Joly","year":"2003","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib55","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.04.002_bib57","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.cytogfr.2025.04.002_bib58","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.04.002_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084166","article-title":"Systematic review on tumor microenvironment in glial neoplasm: from understanding pathogenesis to future therapeutic perspectives","volume":"23","author":"Bianconi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.cytogfr.2025.04.002_bib61","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-19-1324","article-title":"Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel","volume":"25","author":"Willis","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.04.002_bib62","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D'Aloia","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2019.05.017","article-title":"Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies","volume":"458","author":"Zhang","year":"2019","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.04.002_bib64","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.04.002_bib65","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.ymthe.2024.03.023","article-title":"High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T cell therapy","volume":"32","author":"Jin","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib66","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6272498","article-title":"Tumor-derived exosomes in immunosuppression and immunotherapy","volume":"2020","author":"Olejarz","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.semcancer.2024.03.001","article-title":"GLUT and HK: two primary and essential key players in tumor glycolysis","volume":"100","author":"Yadav","year":"2024","journal-title":"Semin Cancer Biol."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.04.002_bib68","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining 'T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"15","key":"10.1016\/j.cytogfr.2025.04.002_bib69","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.04.002_bib70","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.04.002_bib71","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"O","year":"2016","journal-title":"Immunity"},{"issue":"303","key":"10.1016\/j.cytogfr.2025.04.002_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med"},{"issue":"7917","key":"10.1016\/j.cytogfr.2025.04.002_bib73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41586-022-04849-0","article-title":"cBAF complex components and MYC cooperate early in CD8(+) T cell fate","volume":"607","author":"Guo","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.04.002_bib74","article-title":"Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors","volume":"4","author":"Jung","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.04.002_bib75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccell.2020.01.006","article-title":"Unraveling the signaling balance of activation and exhaustion of CAR T cells","volume":"37","author":"Scarfo","year":"2020","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.04.002_bib76","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41423-021-00709-5","article-title":"Reversing the mitochondrial stress-induced exhaustion of CD8(+) T cells for improving cancer immunotherapy","volume":"18","author":"Qian","year":"2021","journal-title":"Cell Mol. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.04.002_bib77","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.immuni.2019.09.003","article-title":"Metabolic profiling using stable isotope tracing reveals distinct patterns of glucose utilization by physiologically activated CD8(+) T cells","volume":"51","author":"Ma","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib78","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","article-title":"The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function","volume":"20","author":"Macintyre","year":"2014","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib79","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cmet.2023.12.010","article-title":"Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation","volume":"36","author":"Si","year":"2024","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.04.002_bib80","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/cmi.2008.32","article-title":"Intercellular trogocytosis plays an important role in modulation of immune responses","volume":"5","author":"Ahmed","year":"2008","journal-title":"Cell Mol. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.04.002_bib81","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.04.002_bib82","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib84","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2016.06.003","article-title":"A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery","volume":"235","author":"Bao","year":"2016","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib85","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1038\/s41467-024-51039-9","article-title":"3D live imaging and phenotyping of CAR-T cell mediated-cytotoxicity using high-throughput Bessel oblique plane microscopy","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2025.04.002_bib86","article-title":"Genetic disruption of blimp-1 drastically augments the antitumor efficacy of BCMA-targeting CAR-T cells","author":"Battram","year":"2024","journal-title":"Blood Adv."},{"issue":"670","key":"10.1016\/j.cytogfr.2025.04.002_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn7336","article-title":"BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion","volume":"14","author":"Jung","year":"2022","journal-title":"Sci. Transl. Med"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.04.002_bib88","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","article-title":"Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2025.04.002_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1185618","article-title":"IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities","volume":"14","author":"Harrer","year":"2023","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.04.002_bib90","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41375-022-01676-0","article-title":"Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction","volume":"36","author":"Jiang","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib91","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40364-021-00275-y","article-title":"TOX as a potential target for immunotherapy in lymphocytic malignancies","volume":"9","author":"Liang","year":"2021","journal-title":"Biomark. Res."},{"issue":"7764","key":"10.1016\/j.cytogfr.2025.04.002_bib92","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"7749","key":"10.1016\/j.cytogfr.2025.04.002_bib93","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.cytogfr.2025.04.002_bib94","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.04.002_bib95","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib96","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.04.002_bib97","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.04.002_bib98","first-page":"910.e1","article-title":"CD19\/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed\/refractory aggressive B cell lymphomas","volume":"27","author":"Cao","year":"2021","journal-title":"Transpl. Cell Ther."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.04.002_bib99","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.04.002_bib100","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib101","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.cytogfr.2025.04.002_bib102","doi-asserted-by":"crossref","first-page":"7718","DOI":"10.4049\/jimmunol.0803313","article-title":"A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains","volume":"182","author":"D\u00fcwel","year":"2009","journal-title":"J. Immunol. (Baltim., Md. 1950)"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.04.002_bib103","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41423-024-01198-y","article-title":"4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20","volume":"21","author":"Dou","year":"2024","journal-title":"Cell Mol. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.04.002_bib104","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1172\/JCI136872","article-title":"Replacing CAR-T cell resistance with persistence by changing a single residue","volume":"130","author":"Hsieh","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.04.002_bib105","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.04.002_bib106","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1380764","article-title":"Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer","volume":"7","author":"Priceman","year":"2018","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.04.002_bib107","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.04.002_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"issue":"18","key":"10.1016\/j.cytogfr.2025.04.002_bib109","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121322","article-title":"4-1BB enhancement of CAR T function requires NF-\u03baB and TRAFs","volume":"3","author":"Li","year":"2018","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.04.002_bib110","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual Targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.04.002_bib111","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.04.002_bib112","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"issue":"287","key":"10.1016\/j.cytogfr.2025.04.002_bib113","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.04.002_bib114","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4049\/jimmunol.1900496","article-title":"T Cell-activating bispecific antibodies in cancer therapy","volume":"203","author":"Trabolsi","year":"2019","journal-title":"J. Immunol. (Baltim., Md.: 1950)"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.04.002_bib115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","article-title":"Blinatumomab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"issue":"27","key":"10.1016\/j.cytogfr.2025.04.002_bib116","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.04.002_bib117","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.04.002_bib118","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.04.002_bib119","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bjh.18654","article-title":"Relapsed and refractory multiple myeloma: a systematic review and network meta-analysis of the efficacy of novel therapies","volume":"200","author":"Minakata","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.04.002_bib120","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.04.002_bib121","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.04.002_bib122","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+\u2009T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.04.002_bib123","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125000450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125000450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:36:29Z","timestamp":1762371389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":123,"alternative-id":["S1359610125000450"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.04.002","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms underlying resistance to CAR-T cell therapy and strategies for enhancement","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}